Engineering CAR-T therapies for autoimmune disease and beyond
- 30 October 2024
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (771) , eado2084
Abstract
Chimeric antigen receptor–T cell (CAR-T) therapy has transformed the management of refractory hematological malignancies. Now that targeting pathogenic cells of interest with antigen-directed cytotoxic T lymphocytes is possible, the field is expanding the reach of CAR-T therapy beyond oncology. Recently, breakthrough progress has been made in the application of CAR-T technology to autoimmune diseases, exploiting the same validated targets that were used by pioneering CAR-T therapies in hematology. Here, we discuss recent advances and outcomes that are paving the way for extension to new therapeutic areas, including autoimmunity.Keywords
This publication has 120 references indexed in Scilit:
- Cancer Drug Price and Novelty in Mechanism of ActionJAMA Network Open, 2023
- Insights into product and process related challenges of lentiviral vector bioprocessingBiotechnology and Bioengineering, 2023
- CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase SyndromeJAMA, 2023
- Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extensionJournal of Neurology, 2023
- Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approachesEuropean Journal of Immunology, 2022
- Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020JAMA Internal Medicine, 2022
- Targeting SARS‐CoV‐2 infection through CAR‐T‐like bispecific T cell engagers incorporating ACE2Clinical & Translational Immunology, 2022
- Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018JAMA Internal Medicine, 2021
- Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission durationCancer, 2010
- A Phase II Randomized Study of HIV-Specific T-Cell Gene Therapy in Subjects with Undetectable Plasma Viremia on Combination Antiretroviral TherapyMolecular Therapy, 2002